EXHIBIT 99.1

PRESS RELEASE

CONTACT:
BIONOVO, INC.
JIM STAPLETON, CFO
510-601-2000
INVESTORS@BIONOVO.COM


LIGHTEN UP ENTERPRISES INTERNATIONAL, INC. CHANGES NAME OF PARENT COMPANY TO
BIONOVO, INC.; CHANGES STOCK SYMBOL; HIRES CFO AND ADDS NEW DIRECTOR

Emeryville, CA. June 30, 2005 - Lighten Up Enterprises International, Inc. today
announced that its trading symbol will change from LTUP.OB to BNVI.OB. Lighten
Up's shares will continue to be quoted on the OTC Bulletin Board under the new
symbol. The new symbol is a result of the company's recent name change from
Lighten Up Enterprises International, Inc. to Bionovo, Inc. The new symbol will
take effect on the OTC Bulletin Board at the opening of trading on Friday, July
1, 2005.

On June 29, 2005, we changed our name to Bionovo, Inc. and changed our state of
incorporation to Delaware pursuant to an agreement and plan of merger, dated as
of June 28, 2005, between Lighten Up and Bionovo, Inc. This transaction had been
approved by the holders of a majority of the outstanding common stock of Lighten
Up by written consent in lieu of a special meeting of Lighten Up's shareholders.
Bionovo Biopharmaceuticals, Inc. continues as a wholly-owned, operating
subsidiary of Bionovo, Inc.

James P. Stapleton has agreed to join Bionovo as Chief Financial Officer. Mr.
Stapleton brings with him extensive financial management experience. From
January 2003 to April 2005 Mr. Stapleton was employed at Auxilio, Inc. (OTC BB:
AUXO.OB), where he was the CFO from January 2003 through December 2004. From
1996 through 2002 Mr. Stapleton was employed in a variety of positions for
ProsoftTraining (NasdaqSC: POSO), including Corporate Secretary, Vice President
Investor relations, Chief Financial Officer, and other positions. Mr. Stapleton
was Chief Financial Officer of BioTek Solutions, Inc. from 1995 through February
1996. From 1987 to 1995, Mr. Stapleton was the Chief Financial Officer for
Advantage Life Products, Inc. Mr. Stapleton graduated from the University of
California at Irvine (UCI) with a MBA in 1995, and from the University of
Washington with a BA in Economics in 1985.

"Jim Stapleton will be an excellent addition to Bionovo with his extensive
management and financial background," stated Isaac Cohen, CEO of Bionovo, Inc.

Michael Vanderhoof has agreed to join the Board of Directors of Bionovo. For the
past seven years, Mr. Vanderhoof has been a private investor in early stage
private and public companies. He is currently Chairman of Cambria Asset
Management LLC, a financial advisory and management firm. For the past five
years, he has also served on the Board of Directors of Auxilio, Inc. (OTC BB:
AUXO.OB) Mr. Vanderhoof has over 20 years experience with respect


                                       1


to financing, mergers and acquisitions, and management of emerging growth
companies. He began his career in 1984 as a NASD Registered Representative in
Salt Lake City, Utah.

"We are deeply honored to have an individual with the experience and background
as Mike Vanderhoof on our Board. I especially respect Mike's understanding of
the markets for emerging growth companies such as Bionovo," stated Isaac Cohen,
CEO of Bionovo, Inc.

ABOUT BIONOVO

Bionovo is a drug development company focusing on the discovery of novel
pharmaceutical agents for cancer and women's health. The company's strategy is
to develop new drugs that it derives from natural substances used
therapeutically in non-western medical practice. Bionovo's first drug is
entering phase II clinical testing for menopause, its second has completed phase
I clinical testing for cancer, and these are followed by more than forty
additional drug candidates that the company believes should provide Bionovo with
a sustainable development pipeline of new chemical entities and botanicals.

FORWARD LOOKING STATEMENTS

This release contains certain "forward looking statements", relating to the
business of Bionovo, Inc. which can be identified by the use of forward looking
terminology such as "believes", "expects", or similar expressions. Such forward
looking statements involve known and unknown risks and uncertainties, including
uncertainties relating to product development, regulatory actions or delays, the
ability to obtain or maintain patent or other proprietary intellectual property
protection, market acceptance, physician acceptance, third party reimbursement,
future capital requirements, competition in general and other factors that may
cause actual results to be materially different from those described herein as
anticipated, believed, estimated or expected. Certain of these risks and
uncertainties are or will be described in greater detail in our filings with the
Securities and Exchange Commission. Bionovo, Inc. is under no obligation (and
expressly disclaims any such obligation) to update or alter its forward looking
statements whether as a result of new information, future events or otherwise.


                                     ~xxx~


                                       2